Clinical trials of new medications conducted in developing countries first provoked comment in 1997, when a study of relatively low dose AZT, given late in pregnancy to HIV-positive mothers about to give birth, was compared with treatment with a placebo. By then we knew that high-dose AZT (expensive) given for a longer period during pregnancy had positive consequences for the newborn child. The idea of not treating the controls caused uproar.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
